{
  "ticker": "JNJ",
  "date": "2022-02-28",
  "lookback_days": 14,
  "fetched_at": "2026-02-13T11:44:03.425039",
  "source": "alpha_vantage",
  "article_count": 7,
  "articles": [
    {
      "title": "Wide Moat Stocks Can Get Their Grooves Back",
      "summary": "The VanEck Vectors Morningstar Wide Moat ETF (MOAT) has shown durability amid market turbulence in early 2022 and is outperforming the S&P 500. Analysts believe wide moat equities have the ingredients for continued success, with the ETF's valuation methodology identifying stocks trading at attractive multiples despite their inherent quality. MOAT's sector-agnostic approach and diversified holdings, including non-tech stocks, are helping to buffer against current tech sector weaknesses.",
      "url": "https://www.etftrends.com/tactical-allocation-content-hub/wide-moat-stocks-can-get-their-grooves-back/",
      "source": "ETF Trends",
      "published": "20220228T173722",
      "overall_sentiment_score": 0.306378,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.309887,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.613938
    },
    {
      "title": "J&J, Legend cell therapy approved by FDA for multiple myeloma",
      "summary": "The FDA has approved Carvykti, a CAR-T cell therapy developed by Johnson & Johnson and Legend Biotech, for multiple myeloma. This treatment is the second CAR-T therapy approved for this blood cancer, following Bristol Myers Squibb and 2seventy bioâ€™s Abecma, and is priced at $465,000. J&J anticipates high annual sales and is exploring Carvykti's efficacy in earlier stages of multiple myeloma.",
      "url": "https://www.biopharmadive.com/news/johnson-johnson-legend-carvykti-myeloma-fda-approval/619430/",
      "source": "BioPharma Dive",
      "published": "20220228T172703",
      "overall_sentiment_score": 0.293712,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.330966,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.924762
    },
    {
      "title": "Surabhi Pokhriyal Named Chief Digital Growth Officer at Church & Dwight",
      "summary": "Church & Dwight has appointed Surabhi Pokhriyal as its Chief Digital Growth Officer, where she will lead the company's digital transformation and e-commerce initiatives. Pokhriyal, previously with Colgate-Palmolive and other major consumer goods companies, is tasked with accelerating digital momentum, including e-commerce penetration and M&A integration. She is excited to leverage the company's nimble structure and focused talent to elevate its digital capabilities and expand its brand footprint.",
      "url": "https://consumergoods.com/surabhi-pokhriyal-named-chief-digital-growth-officer-church-dwight",
      "source": "Consumer Goods Technology",
      "published": "20220228T162223",
      "overall_sentiment_score": 0.210837,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.12082,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.583106
    },
    {
      "title": "Companies Finalize $26 Billion Deal With States and Cities to End Opioid Lawsuits (Published 2022)",
      "summary": "The nation's three largest drug distributors and Johnson & Johnson have finalized a $26 billion deal to settle thousands of opioid lawsuits filed by states and local governments. This settlement, second only to the Big Tobacco agreement, will direct at least 85% of the funds towards addiction treatment and prevention, with the first checks expected in early April. The agreement resolves thousands of civil claims, but does not provide separate funds for individual victims.",
      "url": "https://www.nytimes.com/2022/02/25/health/opioids-settlement-distributors-johnson.html",
      "source": "The New York Times",
      "published": "20220225T162143",
      "overall_sentiment_score": 0.24005,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.227606,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.832858
    },
    {
      "title": "Sanofi and GSK plan to ask regulators to authorize their COVID-19 vaccine",
      "summary": "Sanofi and GlaxoSmithKline (GSK) are seeking regulatory authorization for their COVID-19 vaccine candidate, which showed 100% effectiveness against hospitalization and severe disease in trials. Their protein-based vaccine can serve as a primary vaccine or a booster shot, significantly raising antibody levels. This development offers a conventional alternative to existing mRNA and viral vector vaccines.",
      "url": "https://abcnews.go.com/Health/sanofi-gsk-plan-regulators-authorize-covid-19-vaccine/story?id=83061991",
      "source": "ABC News - Breaking News, Latest News and Videos",
      "published": "20220223T145300",
      "overall_sentiment_score": 0.233998,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.113399,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.559432
    },
    {
      "title": "Mixed reality helps GE Healthcare train engineers to service complex equipment",
      "summary": "GE Healthcare, in collaboration with Microsoft MRPP partner Adjacentech Corporation, has developed a mixed-reality training system using HoloLens 2. This system aims to improve training efficiency and knowledge retention for engineers servicing complex medical equipment like CT and MRI scanners in China. By overlaying holographic 3D visualizations onto real-world objects, the solution provides accurate step-by-step guidance, reducing training time and the risk of equipment damage.",
      "url": "https://www.microsoft.com/en/customers/story/1475200924660741619-ge-healthcare-health-provider-azure-iot-hololens-2",
      "source": "Microsoft",
      "published": "20220222T174617",
      "overall_sentiment_score": 0.32551,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.214879,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.602285
    },
    {
      "title": "Money Calls the Shots",
      "summary": "Amnesty International published \"Money Calls the Shots\" on February 14, 2022, updating its assessment of pharmaceutical companies' restrictions on access to Covid-19 vaccines. The report evaluates five leading vaccine manufacturers (AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc.) and, for the first time, includes Chinese producers Sinopharm and Sinovac Biotech Ltd.",
      "url": "https://www.amnesty.org/en/documents/pol40/5140/2022/en/",
      "source": "Amnesty International",
      "published": "20220214T184636",
      "overall_sentiment_score": 0.10218,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.131335,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.72522
    }
  ]
}